Aim: Our objective was to determine changes in bone mineral density (BMD), trabecular bone score (TBS), and body composition after 2 years of therapy with recombinant human insulin-like growth factor-1 (rhIGF-1) in 2 prepubertal children with a complete lack of circulating PAPP-A2 due to a homozygous mutation in PAPP-A2 (p.D643fs25*) resulting in a premature stop codon. Methods: Body composition, BMD, and bone structure were determined by dual-energy X-ray absorptiometry at baseline and after 1 and 2 years of rhIGF-1 treatment. Results: Height increased from 132 to 145.5 cm (patient 1) and from 111.5 to 124.5 cm (patient 2). Bone mineral content increased from 933.40 to 1,057.97 and 1,152.77 g in patient 1, and from 696.12 to 773.26 and 911.51 g in patient 2, after 1 and 2 years, respectively. Wholebody BMD also increased after 2 years of rhIGF-1 from baseline 0.788 to 0.869 g/cm 2 in patient 1 and from 0.763 to 0.829 g/cm 2 in patient 2. After 2 years of treatment, both children had an improvement in TBS. During therapy, a slight increase in body fat mass was seen, with a concomitant increase in lean mass. No adverse effects were reported. Conclusion: Two years of rhIGF-1 improved growth, with a tendency to improve bone mass and bone microstructure and to modulate body composition.
Introduction
Mutations in the gene for pregnancy-associated plasma protein A-2 (PAPP-A2), a metalloproteinase enzyme [1] , produce short stature due to low insulin-like growth factor-1 (IGF-1) availability. Short stature, skeletal abnormalities, and high circulating levels of total IGF-1, IGFBP-3, IGFBP-5, and acid-labile subunit (ALS) characterize this new syndrome. Because PAPP-A2-deficient patients do not exhibit growth hormone (GH) deficiency, they were treated with recombinant human IGF-1 (rhIGF-1) [2] . We previously reported that these children had improved growth with no adverse effects after 1 year of rhIGF-1 administration [2] .
Here, our aim was to assess the effect of 2 years of rhIGF-1 therapy on bone mineral density (BMD) and bone quality, as assessed by trabecular bone score (TBS), as well as body composition in a unique model of 2 children with a complete lack of PAPP-A2 and very low IGF-1 bioavailability.
Subjects and Methods
Two siblings, a prepubertal female (patient 1; chronological age: 10.54 years) and a prepubertal male (patient 2; chronological age: 6 years) with short stature (height SDS -1.10 and -0.96 for age and sex, respectively, but far from their target height in centile 72) were studied. Both patients were born to nonconsanguineous Spanish parents. Length and weight at birth were normal, but postnatally they experienced continuous growth velocity retardation. Phenotype included small chin, modest microcephaly, and long thin digits on hands and feet. Both children had a homozygous frameshift mutation in PAPP-A2 (p.D643fs25*) [1] . Bone age and chronological age were consistent in patient 1 (Δ = -0.21) and slightly delayed in patient 2 (Δ = 1.5). At diagnosis, the height of the female patient was in the normal range (-1.10 SD), but was 1.6 SDS below her expected height. The height of the male patient was also normal (-0.96 SD), but 1.2 SDS below his expected height. Patient 1 started puberty 3 months after starting rhIGF-1 treatment and thus received GnRH analog in order to delay puberty and to potentiate the effect on height.
Whole-body BMD (WB-BMD), lumbar spine BMD (LS-BMD), hip BMD, and femoral neck BMD (FN-BMD) as well as body composition measurements were performed using dual-energy X-ray absorptiometry (DXA; DXA Discovery Wi, software version 13.3; Hologic, Inc., Waltham, MA, USA) before therapy started and at 1 and 2 years after treatment. Data for BMD are expressed adjusting for height-for-age Z scores [3] . Body composition data obtained by DXA (body fat mass, lean mass, and body fat percentage) were compared from baseline to the end of the study [4] . The coefficient of variation was 0.85 for whole body and 0.70 for lumbar spine.
TBS measurements were obtained from DXA lumbar studies using the TBS iNsight software (MedimapsFrance, v3.0). TBS was calculated from the same DXA acquisition and region of interest as those used for LS-BMD. A higher TBS indicates a healthier bone microarchitecture, whereas a lower value suggests a weaker bone structure. Unfortunately, there is no international consensus regarding what constitutes normal or abnormal TBS in children, but for adults it has been proposed that TBS ≥1,350 is normal, TBS values between 1,200 and 1,350 are consistent with partially degraded bone, and TBS ≤1,200 indicates degraded bone [5] .
Results
Height was clearly increased after treatment with rhIGF-1 in both children according to their sex and age and using Spanish tables. For patients 1 and 2, heights were 132 and 111.5 cm at baseline, 139.6 and 118.5 cm after 1 year of treatment, and 145.5 and 124.5 cm at 2 years of rhIGF-1 therapy, respectively. Ultrasound of internal organs (kidney, spleen, and heart) was normal.
Effects of rhIGF-1 on Bone Mineral Content and BMD (Table 1)
The pretreatment BMD was subnormal in both the female (osteoporosis) and male (osteopenia) subject, according to age-and sex-matched references. In patient 1, bone mineral content (BMC) increased from 933.40 g at baseline to 1,057.97 and 1,152.77 g at 1 and 2 years, respectively, with a total increase of 23.4%. In patient 2, BMC increased from 696.12 g at baseline, to 773.26 and 911.51 g at 1 and 2 years, respectively, with a total increase of 30.8%. At baseline, patient 1 had a WB-BMD of 0.788 g/cm 2 , which increased to 0.843 g/cm 2 at 1 year and 0.869 g/cm 2 at 2 years of rhIGF-1 therapy. Patient 1 had a baseline LS-BMD of 0.582 g/ cm 2 and 0.679 g/ cm 2 after 2 years of rhIGF-1 treatment (a 16.8% increase). Total hip BMD and FN-BMD increased from an initial 0.644 and 0.578 g/ cm 2 to 0.688 and 0.582 g/cm 2 , respectively, with an increase of 6.8%. Despite this, the adjusted LS-BMD Z score (-0.3) and total hip Z score (-1.5) were in the low normal range, but her annual increase was acceptable according to national values for age and sex (+0.094 g/cm 2 ) [6] .
The initial WB-BMD in patient 2 was 0.763 g/cm 2 , 0.784 g/cm 2 at 1 year, and 0.829 g/cm 2 at 2 years of rhIGF therapy. Patient 2 had a baseline LS-BMD of 0.488 g/cm 2 and 0.532 g/cm 2 after 2 years. Total hip BMD and FN-BMD were initially 0.596 and 0.572 g/cm 2 and after 2 years of rhIGF-1 treatment 0.708 and 0.646 g/cm 2 , respectively, with a positive change of 8.5% during this period. The annual increase was similar to that described for Spanish children for age and sex (+0.042 g/cm 2 ) [6] . The height-adjusted LS-BMD Z score (-0.4) and total hip score (0.3) were in the normal range.
Effects of rhIGF-1 on TBS
TBS values were compared to normative data from a group of 4,126 healthy Spanish children of both sexes (2,600 girls and 1,520 boys between 1 and 19 years) according to age and sex [Del Rio et al., unpubl. data].
The initial TBS value for patient 1 was in the lower range: 1,223 (normal range: 1,285 ± 0.10). In patient 2, it DOI: 10.1159/000486336 was acceptable: 1,291 (normal range: 1,269 ± 0.10). After 2 years of treatment, patient 2 showed an increase to 1,312, which is above the normal range adjusted for age and sex (1,228 ± 0.11). Patient 1 had a substantial decline in TBS after the first year of treatment (1,147), but after 2 years it increased to 1,337, which is in the normal range for age and sex (1,355 ± 0.08).
Effects of rhIGF-1 on Body Composition
The percentage of total body fat mass was reduced, by -4.5 and -4.7% in patient 1 and 2, respectively, during the first year of rhIGF-1 therapy. During the second year of treatment, a nonsignificant increase in the percentage of total body mass was found in patient 1 (+2.7%) and in patient 2 (+1.3%), with the percentage of total body fat mass being below the expected value for age and sex in both. The small positive effects of rhIGF-1 on fat mass during the second year could reflect the severe nature of their IGF-1 deficiency [7] . There was a concomitant increase in lean mass from 15,471.8 g at baseline to 19,490.5 and 22,165.6 g after 1 and 2 years of rhIGF-1 treatment in patient 1 and from 11,468.3 g at baseline to 13,892.2 and 16,019.3 g in patient 2. The increases in lean mass in patient 1 (43%) and in patient 2 (40%) during the treatment period are acceptable according to age and sex reference published database [8] .
No adverse effects were seen during rhIGF-1 therapy in either patient. There were no episodes of symptomatic hypoglycemia or hyperglycaemia reported during the 2 years of the study and no local reactions at the site of subcutaneous injections were seen.
Discussion
This is the first study confirming an improvement in BMD, body composition, and microstructure in patients with short stature due to mutations in PAPP-A2 after 2 years of treatment with rhIGF-1. The therapeutic option of rhIGF-1 seems reasonable, as this syndrome is associated with postnatal growth failure and low free IGF-1 bioavailability necessary for bone remodeling during development [9] . Low levels of free IGF-1 are detrimental to bone, as it is fundamental for optimizing peak bone mass. Therefore, it is essential to consider therapeutic interventions to optimize bone mass accrual and bone density during these development years.
Our 2-year study demonstrates that rhIGF-1 treatment is capable of improving WB-BMD, BMC, and LS-BMD towards the normal range and results in an acceptable annual BMD increase. This trend toward increasing BMD of the whole skeleton is similar to previous observations of treatment with rhIGF-1 in other growth-retarded conditions [10] .
In a recent study, Cabrera-Salcedo et al. [11] reported a moderate increase in total BMD in a patient with a missense mutation in PAPP-A2 after 1 year of treatment. The differential response to rhIGF-1 treatment, including a lower growth velocity than that of our patients [2] , could be explained by the differences in the affectation of the IGF-1 system due to the different genetic mutations. Indeed, our patients have a total lack of PAPP-A2 compared to a mutated form of this protease in the patient reported by Cabrera-Salcedo et al. [11] . Although the descriptions of this patient and his brother and sister were published together with the two Spanish subjects, our patients have been under treatment for a longer period due to their earlier diagnosis [1, 12] , and it will be of interest to see how the other patient responds to longer treatment.
Although initially there was a slight decrease in TBS in patient 1, with that of patient 2 being acceptable 1 year after rhIGF-1 treatment, afterwards there was an increase in both children that resulted in a TBS score in the normal range after 2 years of therapy. The small decrease in TBS in patient 1 at 1 year could possibly be due to rhIGF-1 initially increasing bone remodeling. Our study suggests that TBS and BMD may need more than 2 years of therapy to improve significantly, as reported for treatment in other chronic conditions [5] . Preliminary data show an improvement in fracture prediction in adults when TBS is used in combination with FRAX [13] , but the utility of this technique has not been evaluated in children. Longer studies in large series of children with healthy and chronic diseases are necessary to analyze the relationship between TBS and anthropometric clinical variables. Unfortunately, results of TBS cannot be compared with the study by Cabrera-Salcedo et al. [11] as this analysis was not performed.
After the first year of rhIGF-1 treatment, a small decrease in the percentage of body fat mass (<5%) was registered, but in the second year there was a nonsignificant increase (<3%) in both children. This is similar to a recent study, in which an early decrease in the percentage of body fat, followed by a longer-term increase, was reported in 21 children with GH receptor deficiency treated with rhIGF-1 for 3 years [14] . In patients with GH insensitivity syndrome, a small reduction in 3 patients and a 7% rise in the percentage of body fat in 1 patient were found as early as 3 months after treatment with IGF-1 [15] .
Lean mass also increased in both patients, confirming the anabolic effects of IGF-1. The observed increases were normal compared to age-matched controls and similar to those described by others. The significant increase in lean body mass, but no change in BMI, is similar to that reported in GH-deficient patients treated with GH [8] . DXA was used to measure body composition, as this technology is a sensitive tool with good precision for assessment of longitudinal changes [16] .
When we compare the BMD of these patients with PAPP-A2 deficiency to that of our patients with primary ALS deficiency due to recessive IGFALS mutations associated with low IGF-1 levels, differences can be observed. Even without therapy (neither hGH nor rhIGF-1), no affectation of whole-body BMC or LS-BMD was observed in our patients, with the exception of 1 patient who exhibited a very moderately decreased lumbar spine BMC, but not whole-body BMC, as found by DXA analysis [17] . In contrast, a modest decrease in the BMC of the lumbar spine was found in the first reported patient with primary ALS deficiency due to a homozygous IGFALS mutation [18] as well as in 2 male siblings born to consanguineous parents [19] . Thus, we can speculate that the availability of IGF-1 is important for BMD and that, although our 2 patients have very high total IGF-1 levels, IGF-1 availability is very low due to the complete lack of PAPP-A2 deficiency [1] .
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In summary, our study indicates that rhIGF-1 increased growth in 2 children lacking PAPP-A2 and hence with free/bioactive IGF-1 deficiency, with a tendency to improve bone mass, quality of bone, and body composition. Nonetheless, a follow-up of these patients will be required to demonstrate whether they can normalize BMD and TBS as well as to determine their final height. In addition, further research is necessary to evaluate the clinical significance of BMD and TBS changes during growth as a useful tool for the management of these children with this new syndrome.
